Psyence Biomedical
PBMPsyence Biomedical Ltd. (PBM) is a Canadian life science biotechnology company. Its primary business focus is the development of natural psilocybin-derived investigational drug candidates for the treatment of psychological trauma and other mental health conditions. The company is publicly traded on the Canadian Securities Exchange under the ticker symbol PBM. The company’s lead program is a Phase IIb clinical trial investigating the use of its natural psilocybin drug candidate as a potential treatment for adjustment disorder due to a recent diagnosis of incurable cancer. This specific condition, which involves significant psychological distress following a severe medical diagnosis, represents a key therapeutic area for the company. Psyence Biomedical operates a commercial research and production facility for the growth of *Psilocybe cubensis* mushrooms, which are used to produce its natural psilocybin active pharmaceutical ingredient. Psyence Biomedical’s clinical development strategy is conducted through its subsidiary, Psyence Therapeutics Inc., which holds a Clinical Trial Application authorization from Health Canada. The company’s research and development activities are centered on creating standardized, pharmaceutical-grade psilocybin-based treatments intended for use within a medically supervised framework.
PBM · Stock Price
Historical price data
About
Psyence Biomedical Ltd. (PBM) is a Canadian life science biotechnology company. Its primary business focus is the development of natural psilocybin-derived investigational drug candidates for the treatment of psychological trauma and other mental health conditions. The company is publicly traded on the Canadian Securities Exchange under the ticker symbol PBM. The company’s lead program is a Phase IIb clinical trial investigating the use of its natural psilocybin drug candidate as a potential treatment for adjustment disorder due to a recent diagnosis of incurable cancer. This specific condition, which involves significant psychological distress following a severe medical diagnosis, represents a key therapeutic area for the company. Psyence Biomedical operates a commercial research and production facility for the growth of *Psilocybe cubensis* mushrooms, which are used to produce its natural psilocybin active pharmaceutical ingredient. Psyence Biomedical’s clinical development strategy is conducted through its subsidiary, Psyence Therapeutics Inc., which holds a Clinical Trial Application authorization from Health Canada. The company’s research and development activities are centered on creating standardized, pharmaceutical-grade psilocybin-based treatments intended for use within a medically supervised framework.